Duke University biomedical engineers have been able to repair a defect responsible for one of the most common inherited disorders, Duchenne muscular dystrophy
Using a novel genetic ‘editing’ technique, Duke University biomedical engineers have been able to repair a defect responsible for one of the most common inherited disorders, Duchenne muscular dystrophy, in cell samples from Duchenne patients.
Instead of the common gene therapy approach of adding new genetic material to “override” the faulty gene, the Duke scientists have developed a way to change the existing mutated gene responsible for the disorder into a normally functioning gene. The Duke researchers believe their approach could be safer and more stable than current methods of gene therapy.
The researchers are now conducting further tests of this new approach in animal models of the disease.
Duchenne muscular dystrophy is a genetic disease affecting one in 3,600 newborn males. The genetic mutation is found on the X chromosome, of which males have only one copy. (Females, with two X chromosomes, presumably have at least one good copy of the gene.)
Patients with Duchenne muscular dystrophy cannot produce the protein known as dystrophin, which is essential in maintaining the structural integrity of muscle fibers. Over time, patients with the disorder suffer gradual muscle deterioration, which leads to paralysis and eventual death, usually by age 25.
“Conventional genetic approaches to treating the disease involve adding normal genes to compensate for the mutated genes,” said Charles Gersbach, assistant professor of biomedical engineering at Duke’s Pratt School of Engineering and Department of Orthopaedic Surgery and member of Duke’s Institute for Genome Sciences and Policy. “However, this can cause other unforeseen problems, or the beneficial effect does not always last very long.
“Our approach actually repairs the faulty gene, which is a lot simpler,” said David Ousterout, the Duke biomedical engineering graduate student in the Gersbach lab who led the work. “It finds the faulty gene, and fixes it so it can start producing a functional protein again.”
The results of the Duke study were published online in Molecular Therapy, the journal of the American Society for Gene and Cell Therapy. The project was supported by the Hartwell Foundation, the March of Dimes Foundation and the National Institutes of Health.
The Duke experiments, which were carried out in cell samples from Duchenne muscular dystrophy patients, were made possible by using a new technology for building synthetic proteins known as transcription activator-like effector nucleases (TALENs), which are artificial enzymes that can be engineered to bind to and modify almost any gene sequence.
These TALENs bind to the defective gene, and can correct the mutation to create a normally functioning gene.
“There is currently no effective treatment for this disease,” Gersbach said. “Patients usually are in a wheelchair by the age of ten and many die in their late teens or early twenties.”
Duchenne muscular dystrophy has been extensively studied by scientists, and it is believed that more than 60 percent of patients with this type of mutation can be treated with this novel genetic approach.
The Latest Bing News on:
Duchenne muscular dystrophy
- Music Heals 2024 – A Decade of Healing in Support of Muscular Dystrophy Researchon May 9, 2024 at 8:41 am
Join us in celebrating the 10-year milestone of Music Heals! With love and in support of our friend Kadey Schultz and her family, and for ALL families fighting to end Duchenne Muscular Dystrophy, ...
- ASGCT 2024: Kate Therapeutics Unveils Gene Therapy Platform and Product Pipeline Progresson May 9, 2024 at 7:00 am
KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures.
- Dosing paused in Pfizer DMD gene therapy trial after patient deathon May 9, 2024 at 6:30 am
Pfizer is pausing dosing of its DMD gene therapy candidate in a clinical trial while investigating the death of a boy who had received it.
- Young Patient Dies After Receiving Pfizer Gene Therapyon May 9, 2024 at 6:13 am
Tragedy has struck during an important Pfizer medical trial when a young boy suffered a fatal sudden cardiac arrest after receiving experimental gene therapy, according to Reuters, and this death has ...
- 'He was a part of us' | Community mourns loss of high school football iconon May 9, 2024 at 5:35 am
Kent Spiess, 38, passed away on April 19 from a long battle with Duchenne Muscular Dystrophy. He routinely cheered on the Tigers from his wheelchair in the end zone.
- Boy Dosed with Pfizer DMD Gene Therapy Dies a Year after Phase II Trialon May 7, 2024 at 11:19 pm
Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate fordadistrogene movaparvovec after acknowledging the sudden death of a young ...
- Young boy dies in trial for Pfizer Duchenne gene therapyon May 7, 2024 at 2:57 pm
A boy with Duchenne muscular dystrophy died after receiving a Pfizer experimental gene therapy. The company is pausing its trial in older boys.
- Pfizer reports patient death in Duchenne gene therapy studyon May 7, 2024 at 2:49 pm
A young patient died due to cardiac arrest after receiving Pfizer's experimental gene therapy being tested in a mid-stage trial for a muscle-wasting disorder called Duchenne muscular dystrophy(DMD), ...
- Patient dies in Pfizer study of Duchenne gene therapyon May 7, 2024 at 2:39 pm
Pfizer said the patient, a young boy who was treated earlier last year, had died suddenly. The company is working with trial researchers to investigate further.
- Pfizer’s Duchenne Gene Therapy Trial Faces Setback As Young Participant Dieson May 7, 2024 at 1:36 pm
Pzifer said the drug concerned was fordadistrogene movaparvovec (PF-06939926) an investigational gene therapy developed by the company. They added that they have stopped giving that particular dose to ...
The Latest Google Headlines on:
Duchenne muscular dystrophy
[google_news title=”” keyword=”Duchenne muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Transcription activator-like effector nucleases
- Activation of innate immunity: Important piece of the puzzle identifiedon May 1, 2024 at 5:00 pm
LMU researchers have deciphered the complex interplay of various enzymes around the innate immune receptor toll-like receptor 7 (TLR7), which plays an important role in defending our bodies against ...
- Cell Culture – News and Featureson May 1, 2024 at 9:52 am
Patent covers nucleic acids encoding Transcription Activator-Like Effector Nuclease fusion proteins (TALENS) and the formal launch of an associated sublicensing program. PBS Biotech has signed an ...
- T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Needon April 29, 2024 at 5:59 pm
"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of ...
- SPARDA: A Programmable Nucleic Acid Targeting Technology Like CRISPRon April 16, 2024 at 9:14 am
It was shown that the pAgos can form a heterodimeric complex with co-encoded effector nucleases called SPARDA. Like CRISPR-Cas, SPARDA can be activated to cleave collateral ssDNA, dsDNA ...
- Allergic to Eggs? Not These Eggson December 20, 2023 at 4:13 pm
To make their safer egg, the scientists used an enzyme known as TALEN (transcription activator-like effector nuclease). It’s similar to CRISPR in that it snips and edits genetic code according to set ...
- Faculty Participantson October 15, 2023 at 5:03 pm
Its key resource is a small but chemically diverse set of nuclease inhibitors and their analogs ... and environmental factors that lead from acute inflammation to chronic activation of the immune ...
- Driving the future of CAR-T cell therapieson June 11, 2019 at 12:11 pm
Whereas many in the field have used gene-editing technologies such as transcription activator-like effector nucleases (TALENs), zinc finger nucleases or CRISPR–Cas9 to eliminate the TCR gene ...
- Kite and Sangamo come together in $3bn cancer gene editing allianceon February 21, 2018 at 4:00 pm
This is an approach already being pursued by rival CAR-T company Cellectis, which uses its own proprietary gene-editing platform, transcription activator-like effector nuclease (TALEN), though its ...
- From restriction enzymes to CRISPR-Cas9on January 21, 2018 at 12:49 am
Although there are different methods available for doing this, only a few research laboratories in the world are able to produce customized zinc finger nucleases. Transcription activator-like effector ...
- Discoveries in DNA: What's New Since You Went to High School?on March 16, 2017 at 11:00 am
are fused in tandem to one another and to a nuclease subunit. Another protein-based targeting strategy, TALENs, is based on the transcription activator-like effector (proteins secreted by Xanthomonas ...
The Latest Google Headlines on:
Transcription activator-like effector nucleases
[google_news title=”” keyword=”transcription activator-like effector nucleases” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]